Literature DB >> 28986720

The Role of Metabolic Surgery in Non-alcoholic Steatohepatitis Improvement.

Pedro Paulo Caravatto1, Ricardo Cohen2.   

Abstract

PURPOSE OF REVIEW: Non-alcoholic fatty liver disease (NAFLD) is frequently associated with obesity and overweight. It has a broad spectrum of clinical and histological presentations, such as steatosis, inflammation (known as non-alcoholic steatohepatitis or NASH), fibrosis, and cirrhosis. There is increasing evidence that marked weight loss following bariatric surgery is associated with NASH resolution; however, little is known about the mechanisms that may lead to this beneficial condition and if it is due to weight loss alone. In this review, the authors present the latest data regarding NASH resolution following metabolic surgery and try to answer the following questions: is NASH resolution due to weight loss alone or is it related to weight-independent effects similarly to T2D? In such case, can NASH be considered as a sole criterion for metabolic surgery? RECENT
FINDINGS: Most data evaluating NAFLD and bariatric and metabolic surgery are derived from cohort studies. Available data are extremely variable, but in general show a dramatic regression of steatosis, inflammatory changes, and in some cases even fibrosis that is probably linked to major weight loss following surgery. There are no randomized controlled trials evaluating the effects of metabolic surgery over NASH vs. lifestyle modifications. To consider NASH a sole indication for metabolic surgery regardless of BMI, such studies are desperately needed and should be the primary focus of future research in metabolic surgery.

Entities:  

Keywords:  Metabolic surgery; Non-alcoholic fatty liver disease; Steatohepatitis

Mesh:

Year:  2017        PMID: 28986720     DOI: 10.1007/s11883-017-0681-y

Source DB:  PubMed          Journal:  Curr Atheroscler Rep        ISSN: 1523-3804            Impact factor:   5.113


  51 in total

1.  Metabolic surgery for non-obese type 2 diabetes: incretins, adipocytokines, and insulin secretion/resistance changes in a 1-year interventional clinical controlled study.

Authors:  Bruno Geloneze; Sylka Rodovalho Geloneze; Elinton Chaim; Fernanda Filgueira Hirsch; Ana Claudia Felici; Giselle Lambert; Marcos Antonio Tambascia; José Carlos Pareja
Journal:  Ann Surg       Date:  2012-07       Impact factor: 12.969

Review 2.  Is weight reduction an effective therapy for nonalcoholic fatty liver? A systematic review.

Authors:  Rex T Wang; Ronald L Koretz; Hal F Yee
Journal:  Am J Med       Date:  2003-11       Impact factor: 4.965

3.  Randomized placebo-controlled clinical trial of lorcaserin for weight loss in type 2 diabetes mellitus: the BLOOM-DM study.

Authors:  Patrick M O'Neil; Steven R Smith; Neil J Weissman; Meredith C Fidler; Matilde Sanchez; Jinkun Zhang; Brian Raether; Christen M Anderson; William R Shanahan
Journal:  Obesity (Silver Spring)       Date:  2012-03-16       Impact factor: 5.002

4.  Non-alcoholic steatohepatitis: effect of Roux-en-Y gastric bypass surgery.

Authors:  Kevin B Barker; Nicole A Palekar; Steven P Bowers; Joel E Goldberg; Joseph P Pulcini; Stephen A Harrison
Journal:  Am J Gastroenterol       Date:  2006-02       Impact factor: 10.864

Review 5.  Biomarkers in nonalcoholic fatty liver disease-the emperor has no clothes?

Authors:  Madhusudana Girija Sanal
Journal:  World J Gastroenterol       Date:  2015-03-21       Impact factor: 5.742

Review 6.  The prevalence of nonalcoholic fatty liver disease in the Americas.

Authors:  Jorge A López-Velázquez; Karen V Silva-Vidal; Guadalupe Ponciano-Rodríguez; Norberto C Chávez-Tapia; Marco Arrese; Misael Uribe; Nahum Méndez-Sánchez
Journal:  Ann Hepatol       Date:  2014 Mar-Apr       Impact factor: 2.400

7.  Roux-en-Y gastric bypass improves liver histology in patients with non-alcoholic fatty liver disease.

Authors:  Jeanne M Clark; Amir R A Alkhuraishi; Steven F Solga; Patricia Alli; Anna Mae Diehl; Thomas H Magnuson
Journal:  Obes Res       Date:  2005-07

8.  Diabetes remission and reduced cardiovascular risk after gastric bypass in Asian Indians with body mass index <35 kg/m(2).

Authors:  Shashank S Shah; Jayashree S Todkar; Poonam S Shah; David E Cummings
Journal:  Surg Obes Relat Dis       Date:  2009-09-03       Impact factor: 4.734

9.  Dietary fat and carbohydrates differentially alter insulin sensitivity during caloric restriction.

Authors:  Erik Kirk; Dominic N Reeds; Brian N Finck; S Mitra Mayurranjan; Mitra S Mayurranjan; Bruce W Patterson; Samuel Klein
Journal:  Gastroenterology       Date:  2009-01-25       Impact factor: 22.682

Review 10.  Obesity and nonalcoholic fatty liver disease: biochemical, metabolic, and clinical implications.

Authors:  Elisa Fabbrini; Shelby Sullivan; Samuel Klein
Journal:  Hepatology       Date:  2010-02       Impact factor: 17.425

View more
  3 in total

Review 1.  [Bariatric surgery: Expectations and therapeutic goals-a contradiction?]

Authors:  I Hering; C Stier; F Seyfried
Journal:  Chirurg       Date:  2018-08       Impact factor: 0.955

2.  A Pilot Study of Serum Sphingomyelin Dynamics in Subjects with Severe Obesity and Non-alcoholic Steatohepatitis after Sleeve Gastrectomy.

Authors:  Bruno Ramos-Molina; Daniel Castellano-Castillo; Oscar Pastor; Luis Ocaña-Wilhelmi; Diego Fernández-García; Manuel Romero-Gómez; Fernando Cardona; Francisco J Tinahones
Journal:  Obes Surg       Date:  2019-03       Impact factor: 4.129

Review 3.  Metabolic syndrome and liver disease in the era of bariatric surgery: What you need to know!

Authors:  Ioannis A Ziogas; Konstantinos Zapsalis; Dimitrios Giannis; Georgios Tsoulfas
Journal:  World J Hepatol       Date:  2020-10-27
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.